Boehringer Ingelheim and Lilly announced that a new clinical trial is being planned to evaluate Jardiance (empagliflozin) tablets for the treatment of patients with chronic kidney disease (CKD) both with and without type 2 diabetes. In addition, the companies are conducting other mechanistic studies that will evaluate the potential mechanisms by which empagliflozin may affect renal outcomes in patients with CKD (i.e., decreasing glomerular pressure).
Jardiance, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is currently approved as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease.
In the EMPA-REG OUTCOME trial (n>7,000), Jardiance was found to lower the risk for new-onset or worsening of kidney disease by 39% vs. placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease. Standard of care included glucose-lowering agents and cardiovascular agents. The trial was not intended to assess empagliflozin mechanisms on renal outcomes but the kidney assessment was part of a pre-specified exploratory analysis of additional endpoints.
Jardiance is available as 10mg and 25mg strength tablets in 30- and 90-count bottles.
For more information call (800) 243-0127 or visit Jardiance.com.